OVID - オ―ビッド・セラピュ―ティクス (Ovid Therapeutics Inc.) オ―ビッド・セラピュ―ティクス

 OVIDのチャート


 OVIDの企業情報

symbol OVID
会社名 Ovid Therapeutics Inc (オ―ビッド・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 オービッド・セラピューティクス(Ovid Therapeutics Inc.)はバイオ医薬品企業。同社はまれな神経学的障害患者ための医薬品の開発に従事する。同社のリード薬剤候補はOV101で、第2のリードドラッグ候補はOV935である。OV101(ガボクサドール)はデルタ選択的なGABAA受容体作用薬である。同社が潜在的に持続性抑制を回復させ、障害症状を緩和するために、アンジェルマン症候群と脆弱X症候群に応用するOV101は現在開発中である。同社はアンジェルマン症候群の成人でOV101の第II相STARS試験とアンジェルマン症候群または脆弱X症候群の若者でPhase I試験を開始した。同社は武田薬品工業と協力して、まれなてんかん性脳症の治療薬OV935を開発する。   オ―ビッド・セラピュ―ティクスは米国のバイオ医薬品企業。主に中枢神経系疾患の治療薬の開発を行う。候補薬には、アンジェルマン症候群及び脆弱X症候群を対象とした「OV101」、そしてドラベ症候群、レノックス・ガスト―症候群、結節性硬化症などの希少てんかん性脳症を対象とする「OV935」(TAK-935)がある。本社はニューヨーク。   
本社所在地 1460 Broadway Suite 15044 New York NY 10036 USA
代表者氏名 Jeremy Max Levin ジェレミーマックスレビン
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 646-661-7661
設立年月日 41730
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数
url www.ovidrx.com
nasdaq_url https://www.nasdaq.com/symbol/ovid
adr_tso
EBITDA EBITDA(百万ドル) -46.99967
終値(lastsale) 5.99
時価総額(marketcap) 147545554.21
時価総額 時価総額(百万ドル) 151.73300
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 89.13840
当期純利益 当期純利益(百万ドル) -36.89227
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Ovid Therapeutics Inc revenues was not reported. Net loss decreased 41% to $26.1M. Lower net loss reflects Research and development decrease of 56% to $16.6M (expense) Interest income increase from $63K to $522K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$3.18 to -$1.06.

 OVIDのテクニカル分析


 OVIDのニュース

   Ovid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological Conditions  2021/04/19 13:16:52 Benzinga
Ovid Therapeutics Inc (NASDAQ: OVID ) has announced to discontinue the development of OV101 (gaboxadol), a delta (δ)-selective GABAA receptor agonist, in Angelman syndrome and Fragile X syndrome. The company says that while OV101 was well tolerated, with no significant safety signals observed, the company believes that efficacy outcomes observed in these trials do not support its further development. Now, the company … Full story available on Benzinga.com
   Riassunto: Takeda si assicura i diritti globali da Ovid Therapeutics per sviluppare e commercializzare soticlestat per il trattamento di bambini e adulti affetti da sindrome di Dravet e sindrome di Lennox-Gastaut  2021/03/04 01:08:00 Business Wire
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) e Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), una società biofarmaceutica imp
   Samenvatting: Takeda verzekert wereldwijde rechten van Ovid Therapeutics om Soticlestat te ontwikkelen en te commercialiseren voor de behandeling van kinderen en volwassenen met het syndroom van Dravet en het syndroom van Lennox-Gastaut  2021/03/03 14:54:00 Business Wire
OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) en Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovidius”), een biofarmaceutisch bedrijf dat zich voor het ontwikkelen van geneesmiddelen die het leven van mensen met zeldzame neurologische aandoeningen veranderen, kondigde vandaag aan dat Takeda een exclusieve overeenkomst is aangegaan waarbij Takeda bij sluiting van Ovidius wereldwijde rechten zal verwerven om de onderzoeksgeneeskunde soti
   EFFECT - Ovid Therapeutics Inc. (0001636651) (Filer) - Stocks News Feed  2020/11/23 05:18:50 Stocks News Feed
Accepted 2020-11-23 00:18:50 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2020-11-20 Registration Form S-3 Document Format Files Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381 Ovid Therapeutics Inc. (Filer) CIK: 0001636651… Read More »EFFECT – Ovid Therapeutics Inc. (0001636651) (Filer)
   Short Interest in Ovid Therapeutics Inc (NASDAQ:OVID) Rises By 20.8%  2020/10/20 18:26:43 The Olympia Report
Ovid Therapeutics Inc (NASDAQ:OVID) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 4,240,000 shares, a growth of 20.8% from the September 15th total of 3,510,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 4.2 days. […]
   Riassunto: Takeda si assicura i diritti globali da Ovid Therapeutics per sviluppare e commercializzare soticlestat per il trattamento di bambini e adulti affetti da sindrome di Dravet e sindrome di Lennox-Gastaut  2021/03/04 01:08:00 Business Wire
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) e Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), una società biofarmaceutica imp
   Samenvatting: Takeda verzekert wereldwijde rechten van Ovid Therapeutics om Soticlestat te ontwikkelen en te commercialiseren voor de behandeling van kinderen en volwassenen met het syndroom van Dravet en het syndroom van Lennox-Gastaut  2021/03/03 14:54:00 Business Wire
OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) en Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovidius”), een biofarmaceutisch bedrijf dat zich voor het ontwikkelen van geneesmiddelen die het leven van mensen met zeldzame neurologische aandoeningen veranderen, kondigde vandaag aan dat Takeda een exclusieve overeenkomst is aangegaan waarbij Takeda bij sluiting van Ovidius wereldwijde rechten zal verwerven om de onderzoeksgeneeskunde soti
   EFFECT - Ovid Therapeutics Inc. (0001636651) (Filer) - Stocks News Feed  2020/11/23 05:18:50 Stocks News Feed
Accepted 2020-11-23 00:18:50 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2020-11-20 Registration Form S-3 Document Format Files Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381 Ovid Therapeutics Inc. (Filer) CIK: 0001636651… Read More »EFFECT – Ovid Therapeutics Inc. (0001636651) (Filer)
   Short Interest in Ovid Therapeutics Inc (NASDAQ:OVID) Rises By 20.8%  2020/10/20 18:26:43 The Olympia Report
Ovid Therapeutics Inc (NASDAQ:OVID) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 4,240,000 shares, a growth of 20.8% from the September 15th total of 3,510,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 4.2 days. […]
   L'étude ELEKTRA de Phase 2 évaluant le soticlestat (TAK-935/OV935) atteint son critère principal de réduction de la fréquence des crises chez les enfants atteints du syndrome de Dravet ou du syndrome de Lennox-Gastaut  2020/08/26 22:23:00 Business Wire
NEW YORK & OSAKA, Japon--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") et Ovid Therapeutics Inc. (NASDAQ: OVID) ("Ovid"), une société biopharmaceutique s'engageant à développer des médicaments qui transforment la vie des personnes atteintes de maladies neurologiques rares, annoncent ce jour des résultats positifs de l'étude ELEKTRA de Phase 2 randomisée évaluant soticlestat chez des enfants atteints du syndrome de Dravet (SD) ou du syndrome de Lennox-Gast
   EFFECT - Ovid Therapeutics Inc. (0001636651) (Filer) - Stocks News Feed  2020/11/23 05:18:50 Stocks News Feed
Accepted 2020-11-23 00:18:50 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2020-11-20 Registration Form S-3 Document Format Files Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381 Ovid Therapeutics Inc. (Filer) CIK: 0001636651… Read More »EFFECT – Ovid Therapeutics Inc. (0001636651) (Filer)
   Short Interest in Ovid Therapeutics Inc (NASDAQ:OVID) Rises By 20.8%  2020/10/20 18:26:43 The Olympia Report
Ovid Therapeutics Inc (NASDAQ:OVID) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 4,240,000 shares, a growth of 20.8% from the September 15th total of 3,510,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 4.2 days. […]
   L'étude ELEKTRA de Phase 2 évaluant le soticlestat (TAK-935/OV935) atteint son critère principal de réduction de la fréquence des crises chez les enfants atteints du syndrome de Dravet ou du syndrome de Lennox-Gastaut  2020/08/26 22:23:00 Business Wire
NEW YORK & OSAKA, Japon--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") et Ovid Therapeutics Inc. (NASDAQ: OVID) ("Ovid"), une société biopharmaceutique s'engageant à développer des médicaments qui transforment la vie des personnes atteintes de maladies neurologiques rares, annoncent ce jour des résultats positifs de l'étude ELEKTRA de Phase 2 randomisée évaluant soticlestat chez des enfants atteints du syndrome de Dravet (SD) ou du syndrome de Lennox-Gast
   Estudo ELEKTRA de Fase 2 do soticlestat (TAK-935/OV935) cumpre com o endpoint primário, reduzindo a frequência de convulsões em crianças com Síndrome de Dravet ou Síndrome de Lennox-Gastaut  2020/08/26 07:44:00 Business Wire
NOVA YORK (EUA) e OSAKA (Japão)--(BUSINESS WIRE)--A Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), uma empresa biofarmacêutica comprometida com o desenvolvimento de medicamentos que transformam a vida de pessoas com doenças neurológicas raras, anunciou hoje os resultados positivos do estudo ELEKTRA de Fase 2 randomizado do soticlestat em crianças com Síndrome de Dravet (SD) ou Síndrome de Lennox-Gastaut (SLG). O soticlest
   El estudio de fase 2 ELEKTRA de soticlestat (TAK-935/OV935) cumple el criterio de valoración principal de reducir la frecuencia de convulsiones en niños con síndrome de Dravet o síndrome de Lennox-Gastaut  2020/08/26 07:36:00 Business Wire
NUEVA YORK y OSAKA, Japón--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) («Takeda») y Ovid Therapeutics Inc. (NASDAQ: OVID) («Ovid»), una empresa biofarmacéutica comprometida con el desarrollo de medicamentos que transforman la vida de las personas con enfermedades neurológicas poco usuales, han anunciado hoy resultados preliminares positivos del estudio aleatorizado de fase 2 ELEKTRA de soticlestat en niños con síndrome de Dravet (SD) o síndrome de Lennox-Gastaut (

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オ―ビッド・セラピュ―ティクス OVID Ovid Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)